GlobeNewswire

XBiotech Announces Public Offering of Common Shares

Share

AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions.   XBiotech intends to grant the underwriter in the offering a 30-day option to purchase additional common shares.

Piper Jaffray is acting as the sole underwriter in the offering.

Net proceeds of the offering will be used primarily  to advance bermekimab Phase 2 clinical trials in Hidradenitis Suppurativa and Atopic Dermatitis and for general corporate and working capital purposes.   Completion of the offering is subject to customary closing conditions.

The common shares are being offered pursuant to an effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission.  The prospectus supplement and accompanying prospectus relating to the offering contain important information relating to the XBiotech common shares. The prospectus supplement will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov, or may be obtained, when available, by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by email at prospectus@pjc.com, or by phone at (800) 747-3924. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  This offering may only be made by means of a prospectus supplement and related base prospectus.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

 

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor20.8.2019 17:45:00 CESTPress release

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035 This patent strengthens the protection of lanifibranor in the United States Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035. This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protect

PCI Biotech: Invitation to second quarter and first half 2019 results presentation20.8.2019 15:38:00 CESTPress release

Oslo, Norway, 20 August 2019 - PCI Biotech invites to a presentation of the company's second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com. The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 28 August 2019. For further information, please contact: Ronny Skuggedal, CFO Email: rs@pcibiotech.no Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutica

Regarding resignation of member of the Supervisory Board20.8.2019 15:30:00 CESTPress release

We hereby inform that, T. Lukoševičius, a member of Supervisory Board of AB Klaipedos nafta (hereinafter – the Company) 20 August 2019 submitted a notice of resignation of members of Supervisory Board of the Company as of 3 September 2019 (this day is the last day of the mandate). It should be noted that, currently the Supervisory Board of the Company consists of 3 members, 2 of them are independent. After the resignation of T. Lukoševičius, the Ministry of Energy of the Republic of Lithuania will conduct the selection of new member of the Supervisory Board. The Supervisory Board is elected by the General Meeting of Shareholders for 4 years. If individual members of the Supervisory Board are elected, they shall be elected only until the end of the term of office of the current Supervisory Board. Jonas Lenkšas, Chief Financial Officer,+370 694 80594

SERSTECH AB: Boardmember Anna Werntoft resigns from the Board of Serstech20.8.2019 13:40:00 CESTPress release

Anna Werntoft will leave the board of directors effective on the 30th of September. The reason for her resignation is that she enters a new operational position with terms that does not allow external assignments. Serstech wishes Anna all the best in her new position and would like to thank her for her contribution while being on the Serstech Board. The Serstech will consist of three Board members until the vacant position is filled. The search for a replacement has started and will be concluded before the next annual general meeting. For further information, please contact: Stefan Sandor, CEO, Serstech AB tel: +46 739 606067 email: ss@serstech.com Thomas Pileby, Chairman of the Board, Serstech AB tel: +46 702 072643 email: tp@serstech.com Company website: www.serstech.com The information was submitted for publication, through the agency of the contact person set out above at 13:40 CET on August 20, 2019. Certified advisor to Serstech is Västra Hamnen Corporate Finance AB, phone: 040-2